{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:39:20Z","timestamp":1785886760464,"version":"3.56.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Optic neuritis can result from several distinct causes, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody disease (MOGAD), when not idiopathic. This review discusses evidence-based treatment approaches contingent upon each specific cause of optic neuritis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Current evidence highlights the need for prompt plasmapheresis as adjunct to intravenous methylprednisolone (IVMP) in patients with NMOSD-associated optic neuritis. Recent advances have included a proliferation of novel disease modifying therapies (DMTs) for long-term management of NMOSD and an understanding of how existing therapeutic options can be leveraged to optimally treat MOGAD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>In acute idiopathic or MS-associated optic neuritis, IVMP hastens visual recovery, though it does not substantially affect final visual outcomes. IVMP and adjunctive plasmapheresis are beneficial in the treatment of NMOSD-associated optic neuritis, with a shorter time-to-treatment associated with a higher likelihood of recovery. The natural history of untreated MOGAD-associated optic neuritis is unclear but treatment with IVMP is near-universal given phenotypic similarities with NMOSD. Long-term immunosuppressive therapy is warranted in patients with NMOSD as well as in patients with MOGAD with poor visual recovery or recurrent attacks.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/icu.0000000000001007","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T10:14:18Z","timestamp":1697537658000},"page":"73-82","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Evidence-based management of optic neuritis"],"prefix":"10.1097","volume":"35","author":[{"given":"Emilie","family":"Bergeron","sequence":"first","affiliation":[{"name":"Division of Neuro-Ophthalmology, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"D\u00e9partement d\u2019ophtalmologie et d\u2019oto-rhino-laryngologie \u2013 chirurgie cervico-faciale, Facult\u00e9 de m\u00e9decine, Centre Universitaire d\u2019Ophtalmologie, H\u00f4pital du Saint-Sacrement, CHU de Qu\u00e9bec-Universit\u00e9 Laval, Quebec UO-Recherche-Clinique, H\u00f4pital du Saint-Sacrement, Centre de recherche du CHU de Qu\u00e9bec City, Qu\u00e9bec City, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A.","family":"Bouffard","sequence":"additional","affiliation":[{"name":"Division of Neuro-Ophthalmology, Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0161-6420(94)31103-1","article-title":"The course of visual recovery after optic neuritis","volume":"101","author":"Beck","year":"1994","journal-title":"Ophthalmology"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1001\/archopht.1991.01080120057025","article-title":"Optic neuritis study group. The clinical profile of optic neuritis \u2013 experience of the Optic Neuritis Treatment Trial","volume":"109","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/WCO.0000000000000766","article-title":"Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis","volume":"33","author":"Chen","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1056\/NEJM199312093292403","article-title":"The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis","volume":"329","author":"Beck","year":"1993","journal-title":"N Engl J Med"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jamaneurol.2018.0024","article-title":"Effect of treating acute optic neuritis with bioequivalent oral vs intravenous corticosteroids","volume":"75","author":"Morrow","year":"2018","journal-title":"JAMA Neurol"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"9769","DOI":"10.3390\/ijms23179769","article-title":"Treatment and relapse prevention of typical and atypical optic neuritis","volume":"23","author":"Saitakis","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM200009283431301","article-title":"Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis","volume":"343","author":"Jacobs","year":"2000","journal-title":"N Engl J Med"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0140-6736(00)04725-5","article-title":"Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study","volume":"357","author":"Comi","year":"2001","journal-title":"Lancet"},{"key":"R11-20250730","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(09)70237-6","article-title":"Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial","volume":"8","author":"Kappos","year":"2009","journal-title":"Lancet"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(11)70262-9","article-title":"Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial","volume":"11","author":"Comi","year":"2012","journal-title":"Lancet Neurol"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1474-4422(14)70191-7","article-title":"Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Miller","year":"2014","journal-title":"Lancet Neurol"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","article-title":"Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial","volume":"16","author":"Cadavid","year":"2017","journal-title":"Lancet Neurol"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","article-title":"Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Raftopoulos","year":"2016","journal-title":"Lancet Neurol"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12883-020-01645-z","article-title":"Fingolimod after a first unilateral episode of acute optic neuritis (MOVING) \u2013 preliminary results from a randomized, rater-blind, active-controlled, phase 2 trial","volume":"20","author":"Albert","year":"2020","journal-title":"BMC Neurol"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1474-4422(03)00308-9","article-title":"Multiple sclerosis in the Japanese population","volume":"2","author":"Kira","year":"2003","journal-title":"Lancet Neurol"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1212\/WNL.56.4.507","article-title":"MS and neuromyelitis optica in Martinique (French West Indies)","volume":"56","author":"Cabre","year":"2001","journal-title":"Neurology"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2006.06.060","article-title":"Natural history of the visual impairment of relapsing neuromyelitis optica","volume":"114","author":"Merle","year":"2007","journal-title":"Ophthalmology"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International Consensus Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1,153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","article-title":"Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica","volume":"130","author":"Merle","year":"2012","journal-title":"Arch Opthalmol"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ajo.2023.02.013","article-title":"Visual outcomes following plasma exchange for optic neuritis: an international multicenter retrospective analysis of 395 optic neuritis attacks","volume":"252","author":"Chen","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2\u200ayears","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1212\/WNL.0b013e3182152881","article-title":"Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab","volume":"76","author":"Pellkofer","year":"2011","journal-title":"Neurology"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1212\/01.WNL.0000159399.81861.D5","article-title":"An open label study of the effects of rituximab in neuromyelitis optica","volume":"64","author":"Cree","year":"2005","journal-title":"Neurology"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"513","DOI":"10.5692\/clinicalneurol.53.513","article-title":"A case of neuromyelitis optica spectrum disorder developing a fulminant course with multiple white-matter lesions following fingolimod treatment","volume":"53","author":"Izaki","year":"2013","journal-title":"Rinsho Shinkeigaku"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult Scler"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"R36-20250730","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"R37-20250730","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"16727","DOI":"10.1038\/s41598-020-73882-8","article-title":"Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"10","author":"Songwisit","year":"2020","journal-title":"Sci Rep"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult Scler"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1177\/1352458518776584","article-title":"Treating neuromyelitis optica with azathioprine: 20-year clinical practice","volume":"25","author":"Bichuetti","year":"2019","journal-title":"Mult Scler"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1212\/WNL.51.4.1219","article-title":"Devic's neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine","volume":"51","author":"Mandler","year":"1998","journal-title":"Neurology"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1136\/jnnp-2012-304774","article-title":"Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies","volume":"84","author":"Kitley","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"key":"R49-20250730","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jneuroim.2019.04.007","article-title":"Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: a systematic review","volume":"332","author":"Enriquez","year":"2019","journal-title":"J Neuroimmunol"},{"key":"R50-20250730","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41598-017-00860-y","article-title":"Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder","volume":"7","author":"Chen","year":"2017","journal-title":"Sci Rep"},{"key":"R51-20250730","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jns.2016.09.035","article-title":"Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: a prospective cohort study","volume":"370","author":"Xu","year":"2016","journal-title":"J Neurol Sci"},{"key":"R52-20250730","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2169\/internalmedicine.52.7885","article-title":"Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder","volume":"52","author":"Yaguchi","year":"2013","journal-title":"Intern Med"},{"key":"R53-20250730","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcomes","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R54-20250730","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOG-antibody disease: a UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"R55-20250730","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1352458519845112","article-title":"The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults","volume":"26","author":"De Mol","year":"2020","journal-title":"Mult Scler"},{"key":"R56-20250730","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/WNO.0000000000001684","article-title":"The treatment of myelin oligodendrocyte glycoprotein antibody disease: a state-of-the-art review","volume":"42","author":"Chwalisz","year":"2022","journal-title":"J Neuro-Ophthalmol"},{"key":"R57-20250730","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14728214.2021.1919082","article-title":"Emerging drugs for the treatment of adult MOG-IgG-associated diseases","volume":"26","author":"Carnero Contentti","year":"2021","journal-title":"Expert Opin Emerg Drugs"},{"key":"R58-20250730","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J Neuroinflammation"},{"key":"R59-20250730","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"R60-20250730","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R61-20250730","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1212\/WNL.0000000000009758","article-title":"Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder","volume":"95","author":"Chen","year":"2020","journal-title":"Neurology"}],"container-title":["Current Opinion in Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICU.0000000000001007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:01:46Z","timestamp":1753891306000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICU.0000000000001007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,16]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/icu.0000000000001007","relation":{},"ISSN":["1040-8738","1531-7021"],"issn-type":[{"value":"1040-8738","type":"print"},{"value":"1531-7021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,16]]}}}